Molecular basis of agonism and antagonism in the oestrogen receptor
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Oestrogens are involved in the growth, development and homeostasis of a number of tissues. The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER). Hormone binding to the ligand-binding domain (LBD) of the ER initiates a series of molecular events culminating in the activation or repression of target genes. Transcriptional regulation arises from the direct interaction of the ER with components of the cellular transcription machinery. Here we report the crystal structures of the LBD of ER in complex with the endogenous oestrogen, 17beta-oestradiol, and the selective antagonist raloxifene, at resolutions of 3.1 and 2.6 A, respectively. The structures provide a molecular basis for the distinctive pharmacophore of the ER and its catholic binding properties. Agonist and antagonist bind at the same site within the core of the LBD but demonstrate different binding modes. In addition, each class of ligand induces a distinct conformation in the transactivation domain of the LBD, providing structural evidence of the mechanism of antagonism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We previously found that the full-length ERα dimer forms a symmetric tail-to-tail dimer in the ERα/SRC-3/p300 complex (Yi et al., 2015), consistent with the nature of palindromic DNA binding sequence, symmetric X-ray crystal structures of the ERα LBD (Brzozowski et al., 1997) and DBD dimers (Schwabe et al., 1993).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
In the citing paper
“the AR LBD interacts weakly with LXXLL motif-containing coactivators, such as SRCs, (Brzozowski et al., 1997; Dubbink et al., 2006; He et al., 2004; He et al., 1999; Matias et al., 2000; Nadal et al., 2017).”
From Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes (2020) · cites this paper as Brzozowski et al., 1997
Citations
Cites
[20] Processing of X-ray diffraction data collected in oscillation mode
Otwinowski, Z., & Minor, W. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)76066-x · Cited by 33,475 · cited 1×
“Data were integrated and reduced using the programs DENZO and SCALEPAC”
MethodPROCHECK: a program to check the stereochemical quality of protein structures
Laskowski, R. A., MacArthur, M. W., Moss, D. S., & Thornton, J. M. (1993) · Journal of Applied Crystallography · doi:10.1107/s0021889892009944 · Cited by 24,581
The CCP4 suite: programs for protein crystallography
Collaborative Computational Project, N. 4. (1994) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444994003112 · Cited by 17,270
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,742
LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions
Wallace, A. C., Laskowski, R. A., & Thornton, J. M. (1995) · "Protein Engineering, Design and Selection" · doi:10.1093/protein/8.2.127 · Cited by 5,690
MOLECULAR MECHANISMS OF ACTION OF STEROID/THYROID RECEPTOR SUPERFAMILY MEMBERS
Tsai, M.-J., & O'Malley, B. W. (1994) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.63.070194.002315 · Cited by 2,932 · cited 1×
“The physiological effects of these steroids are mediated by a ligand-inducible nuclear transcription factor, the oestrogen receptor (ER”
BackgroundThe estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer
Kumar, V., & Chambon, P. (1988) · Cell · doi:10.1016/0092-8674(88)90017-7 · Cited by 1,220 · cited 1×
“The ER LBDs are arranged as non-crystallographic dimers within both the E 2 and RAL complex crystals in a manner consistent with both the oligomeric state of liganded ER in solutio”
BackgroundCrystal structure of the ligand-binding domain of the human nuclear receptor RXR-α
Bourguet, W., Ruff, M., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/375377a0 · Cited by 1,177 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundCrystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid
Renaud, J.-P., Rochel, N., Ruff, M., Vivat, V., Chambon, P., Gronemeyer, H., & Moras, D. (1995) · Nature · doi:10.1038/378681a0 · Cited by 1,097 · cited 1×
“The overall architecture of the ER LBD (helices H3–H12) is similar to that seen in the crystal structures of other nuclear receptor LBD”
BackgroundA canonical structure for the ligand-binding domain of nuclear receptors
Wurtz, J.-M., Bourguet, W., Renaud, J.-P., Vivat, V., Chambon, P., Moras, D., & Gronemeyer, H. (1996) · Nature Structural Biology · doi:10.1038/nsb0196-87 · Cited by 985 · cited 1×
“, and emphasizes the universal nature of this fold within this receptor superfamil”
Background
Cited by
Items 601–700 of 1,012
Lewis-Wambi, J. S., Kim, H., Curpan, R. F., Grigg, R., Sarker, M. A., & Jordan, V. C. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.072249 · Cited by 128
“Entries 1gwr for E2 (Wärnmark et al., 2002), 1err for RAL (Brzozowski et al., 1997), and 3ert for 4OHT (Shiau et al., 1998) were selected for further modeling, and these structures were prepared for docking using the Protein Preparation Workflow (Friesner et al., 2004; Guallar et al., 2004)…”
MethodSelective Estrogen Receptor Modulators: A Look Ahead
Mitlak, B., & Cohen, F. J. (1999) · Drugs · doi:10.2165/00003495-199957050-00001 · Cited by 128
“[3,16,17] Recently, a solution to the crystalline structure of the ligand-binding domain of ERα (after binding to either 17β-estradiol or to raloxifene) was reported.[3] Akey feature of the structure is the ability of ERα helix 12 in the ligand-binding site (an essential site for AF-2 activation) to fold into the comp…”
BackgroundKumari, N., KUMARI, R. R., Dua, A., Singh, M., Kumar, R., Singh, P., Duyar‐Ayerdi, S., Pradeep, S., Ojesina, A. I., & Kumar, R. (2024) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300688 · Cited by 128
Liao, L., Kuang, S.-Q., Yuan, Y., Gonzalez, S. M., O’Malley, B. W., & Xu, J. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00254-6 · Cited by 127
Role for Hsp90-Associated Cochaperone p23 in Estrogen Receptor Signal Transduction
Knoblauch, R., & Garabedian, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3748 · Cited by 126
“The recent determination of the structure of the ER ligandbinding domain bound to estradiol has suggested that proper folding of this region around the steroid hormone is crucial to the formation of an AF-2 domain competent for interaction with coactivators (3).”
BackgroundIntermolecular interactions identify ligand-selective activity of estrogen receptor α/β dimers
Powell, E., & Xu, W. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807274105 · Cited by 107
Oyster estrogen receptor: cDNA cloning and immunolocalization
Matsumoto, T., Nakamura, A. M., Mori, K., Akiyama, I., Hirose, H., & Takahashi, Y. K. (2007) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2007.01.016 · Cited by 126
Zhao, L., O’Neill, K. E., & Brinton, R. D. (2005) · Brain Research Reviews · doi:10.1016/j.brainresrev.2005.01.009 · Cited by 126
Lappano, R., Recchia, A. G., De Francesco, E. M., Angelone, T., Cerra, M. C., Picard, D., & Maggiolini, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016631 · Cited by 121
Fukuzawa, K., Mochizuki, Y., Tanaka, S., Kitaura, K., & Nakano, T. (2006) · The Journal of Physical Chemistry B · doi:10.1021/jp060770i · Cited by 126
Keeton, E. K., & Brown, M. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0395 · Cited by 104
“In addition, the fact that tamoxifen does not induce recruitment of ER coactivators in breast cancer cells also plays a role in its partial agonism (14, 15, 17).”
Selective oestrogen receptor modulation
Levenson, A. S., & Jordan, V. C. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00183-5 · Cited by 126
Key Structural Features of Nonsteroidal Ligands for Binding and Activation of the Androgen Receptor
Yin, D., He, Y., Perera, M. A., Hong, S., Marhefka, C. A., Stourman, N. V., Kirkovsky, L. I., Miller, D. D., & Dalton, J. T. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.1.211 · Cited by 124
“It is possible, as was suggested for other steroid receptors (Brzozowski et al., 1997), that the AR may respond to agonists and antagonists by positioning helix H12, one of the 12 helices contained in the secondary structure of its LBD, to either seal (in the case of agonists) or open (in the case…”
BackgroundSippl, W. (2000) · Journal of Computer-Aided Molecular Design · doi:10.1023/a:1008115913787 · Cited by 124
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women
Archer, D. F., Lewis, V., Carr, B. R., Olivier, S., & Pickar, J. H. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2009.05.093 · Cited by 123
Assessment of estrogenic activity in some common essential oil constituents
Howes, M. R., Houghton, P. J., Barlow, D. J., Pocock, V., & Milligan, S. R. (2002) · Journal of Pharmacy and Pharmacology · doi:10.1211/002235702216 · Cited by 123
“Helix displacement is regarded as a general feature of hER antagonists (Brzozowski et al 1997 ; McDonnell 1999 ; Wolf & Fuqua 1995).”
BackgroundStender, J. D., Nwachukwu, J. C., Kastrati, I., Kim, Y., Strid, T., Yakir, M., Srinivasan, S., Nowak, J., Izard, T., Rangarajan, E. S., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.02.008 · Cited by 119
“Although the antagonist conformation was originally defined as helix 12 docking into the CoRnR groove to block coactivator binding (Brzozowski et al., 1997; Shiau et al., 1998), we show that it represents the SERM agonist orSERMresistant conformerby virtueof blockingall protein interactions,…”
InfluentialXin, Y., Ren, X.-M., Wan, B., & Guo, L.-H. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.9b01579 · Cited by 118
The cytotoxic necrotizing factor 1 (CNF1) from Escherichia coli
Boquet, P. (2001) · Toxicon · doi:10.1016/s0041-0101(01)00154-4 · Cited by 123
Ligand–protein interactions in nuclear receptors of hormones
Egea, P. F., Klaholz, B. P., & Moras, D. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01672-0 · Cited by 107
Valley, C. C., Métivier, R., Solodin, N. M., Fowler, A. M., Mashek, M. T., Hill, L. M., & Alarid, E. T. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5417-5428.2005 · Cited by 123
“AF-2 is highly structured, consisting of 12 -helices that adopt an active conformation upon agonist binding, which exposes a hydrophobic surface where coactivator proteins bind (6).”
BackgroundLees, M. J., & Whitelaw, M. L. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5811 · Cited by 96
“For example, crystal structures show that binding of estradiol to the estrogen receptor positions the AF-2 transactivation domain correctly for induction of transcription, while antiestrogens produce a conformation which misplaces this domain (4).”
BackgroundThe therapeutic potential of phytoestrogens
Wiseman, H. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.8.1829 · Cited by 122
“The crystal structures of the ligandbinding domain of the oestrogen receptor complexed to either 17β-oestradiol or to raloxifene has been reported [31] thus providing structural evidence for the mechanisms of oestrogen receptor agonism and antagonism.”
BackgroundInteraction of estrogen receptors α and β with estrogen response elements
Loven, M. A., Wood, J. R., & Nardulli, A. M. (2001) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(01)00491-9 · Cited by 122
Inhibition of the dihydrotestosterone-activated androgen receptor by nuclear receptor corepressor.
Cheng, S., Brzostek, S., Lee, S. R., Hollenberg, A. N., & Balk, S. P. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.7.0870 · Cited by 121
SRY Interacts with and Negatively Regulates Androgen Receptor Transcriptional Activity
Yuan, X., Lu, M. L., Li, T., & Balk, S. P. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m108404200 · Cited by 111
Molecular Action of Androgen in the Normal and Neoplastic Prostate
Kokontis, J. M., & Liao, S. (1998) · Vitamins and hormones · doi:10.1016/s0083-6729(08)60937-1 · Cited by 121
Free energies of ligand binding for structurally diverse compounds
Oostenbrink, C., & van Gunsteren, W. F. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407404102 · Cited by 120
Tetradian oscillation of estrogen receptor α is necessary to prevent liver lipid deposition
Villa, A., Della Torre, S., Stell, A., Cook, J., Brown, M., & Maggi, A. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1205797109 · Cited by 101
“The nature of the signal perceived by ERα in fact imposes well-defined spatial conformations, enabling its interaction with the specific coregulators necessary for the selection of a precise gene network (25).”
BackgroundHu, J., & Aizawa, T. (2003) · Water Research · doi:10.1016/s0043-1354(02)00378-0 · Cited by 120
Overexpression, Purification, and Crystal Structure of Native ERα LBD
Eiler, S., Gangloff, M., Duclaud, S., Moras, D., & Ruff, M. (2001) · Protein Expression and Purification · doi:10.1006/prep.2001.1409 · Cited by 120
“One was to use a denaturation–renaturation process (4); the second was to modify chemically the cysteine by carboxymethylation (5).”
BackgroundMethodLu, Y., & Liu, W. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00913 · Cited by 119
Diphenyl quinolines and isoquinolines: synthesis and primary biological evaluation
Croisy‐Delcey, M., Croisy, A., Carrez, D., Huel, C., Chiaroni, A., Ducrot, P., Bisagni, É., Jin, L., & Leclercq, G. (2000) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(00)00194-2 · Cited by 118
Estrogenic Compounds, Estrogen Receptors and Vascular Cell Signaling in the Aging Blood Vessels
Smiley, D., & Khalil, R. A. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709788186093 · Cited by 123
“In terms of precise steric hydrophobic centers mimicking steric C7α and C11β substituents, the volume of the ER binding pocket is about twice that of the E2 molecule [88].”
BackgroundDussault, I., Lin, M., Hollister, K., Fan, M., Termini, J., Sherman, M. A., & Forman, B. M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.15.5270-5280.2002 · Cited by 111
“repression and complete activation (3, 37, 43, 50).”
BackgroundSelective Estrogen Receptor Modulators for Postmenopausal Osteoporosis: Current State of Development
Gennari, L., Merlotti, D., Valleggi, F., Martini, G., & Nuti, R. (2007) · Drugs & Aging · doi:10.2165/00002512-200724050-00002 · Cited by 118
ERAP140, a Conserved Tissue-Specific Nuclear Receptor Coactivator
Shao, W., Halachmi, S., & Brown, M. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3358-3372.2002 · Cited by 104
“In contrast, ER LBD bound by its antagonists, such as tamoxifen and raloxifene, adopts a configuration in which the positioning of helix 12 mimics intramolecular interaction with the AF-2 surface and occludes the coactivator association (7, 42).”
BackgroundTranscriptional complexes engaged by apo‐estrogen receptor‐α isoforms have divergent outcomes
Métivier, R., Penot, G., Carmouche, R. P., Hübner, M. R., Reid, G., Denger, S., Manu, D., Brand, H., Koš, M., Beneš, V., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600377 · Cited by 117
“These sur- faces are included within the two transactivation functions (AFs) of ERs, located in the N- (AF1) and C-terminal (AF2) domains (Brzozowski et al, 1997; Robinson-Rechavi et al, 2003).”
BackgroundCui, J., Yang, Y., Li, H., Leng, Y.-J., Qian, K., Huang, Q., Zhang, C., Zhao, L., Chen, J., Sun, T., et al. (2014) · Oncogene · doi:10.1038/onc.2014.430 · Cited by 116
Transcription Factor Effector Domains
Frietze, S., & Farnham, P. J. (2011) · Subcellular Biochemistry · doi:10.1007/978-90-481-9069-0_12 · Cited by 84
Isomer-Specific Degradation and Endocrine Disrupting Activity of Nonylphenols
Gabriel, F. L. P., Routledge, E. J., Heidlberger, A., Rentsch, D., Günther, K., Giger, W., Sumpter, J. P., & Kohler, H. E. (2008) · Environmental Science & Technology · doi:10.1021/es800577a · Cited by 116
Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis
Sato, M., Grese, T. A., Dodge, J. A., Bryant, H. U., & Turner, C. H. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980344o · Cited by 107
Efficient Incorporation of Protein Flexibility and Dynamics into Molecular Docking Simulations
Lill, M. A. (2011) · Biochemistry · doi:10.1021/bi2004558 · Cited by 104
“selective estrogen receptor modulators (SERM) (Figure 1, bottom right) generates different conformations of helix 12 resulting in tissue-specific control of signals (18).”
BackgroundTamoxifen Resistance in Breast Cancer: Elucidating Mechanisms
Dorssers, L. C. J., van der Flier, S., Brinkman, A., van Agthoven, T., Veldscholte, J., Berns, E. M. J. J., Klijn, J. G. M., Beex, L. V. A. M., & Foekens, J. A. (2001) · Drugs · doi:10.2165/00003495-200161120-00004 · Cited by 116
“dimensional structure in the receptor, which renders it unable to enhance specific gene expression.[26]”
BackgroundTapia-Gonzalez, S., Carrero, P., Pernia, O., Garcia-Segura, L. M., & Diz-Chaves, Y. (2008) · Journal of Endocrinology · doi:10.1677/joe-07-0294 · Cited by 100
van Lipzig, M. M. H., ter Laak, A., Jongejan, A., Vermeulen, N. P. E., Wamelink, M. M. C., Geerke, D. P., & Meerman, J. H. N. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0309607 · Cited by 116
Rational discovery of novel nuclear hormone receptor antagonists
Schapira, M., Raaka, B. M., Samuels, H. H., & Abagyan, R. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1008 · Cited by 116
Wong, C.-W., Komm, B., & Cheskis, B. J. (2001) · Biochemistry · doi:10.1021/bi010379h · Cited by 103
Leers, J., Treuter, E., & Gustafsson, J.-Å. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.6001 · Cited by 104
“As we know from the dimerization interface between the subunits in ERa homodimers, which contains LXXLL motifs, the interaction engages a region of about 12 aa (6).”
BackgroundSelf-citationChemical components of plastics as endocrine disruptors: Overview and commentary
Darbre, P. D. (2020) · Birth Defects Research · doi:10.1002/bdr2.1778 · Cited by 115
A review on phytoestrogens: Current status and future direction
Patra, S., Gorai, S., Pal, S., Ghosh, K., Pradhan, S., & Chakrabarti, S. (2023) · Phytotherapy Research · doi:10.1002/ptr.7861 · Cited by 116
“Additional elements affecting a chemical's ability to bind to the estrogen receptors alpha (ERα) are its placement on the phenolic ring, the degree and extent of branching of the alkyl group, and the range of electron density distribution on the A rings (Brzozowski et al., 1997).”
BackgroundInfluentialProblems for risk assessment of endocrine-active estrogenic compounds.
Safe, S. H., Pallaroni, L., Yoon, K., Gaido, K., Ross, S., & McDonnell, D. (2002) · Environmental Health Perspectives · doi:10.1289/ehp.02110s6925 · Cited by 106
Structure-based Discovery of Antagonists of Nuclear Receptor LRH-1
Benod, C. C., Carlsson, J., Uthayaruban, R., Hwang, P. K., Irwin, J. J., Doak, A. K., Shoichet, B. K., Sablin, E. P., & Fletterick, R. J. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.411686 · Cited by 115
A pharmacophore‐based evolutionary approach for screening selective estrogen receptor modulators
Yang, J., & Shen, T.-W. (2005) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20387 · Cited by 115
Selective estrogen receptor modulators as brain therapeutic agents
Arevalo, M. A., Santos-Galindo, M., Lagunas, N., Azcoitia, I., & Garcia-Segura, L. M. (2011) · Journal of Molecular Endocrinology · doi:10.1677/jme-10-0122 · Cited by 105
“SERMs bind to estrogen receptors (ERs) and induce specific changes in their three-dimensional conformation (Brzozowski et al. 1997, Paige et al. 1999) allowing a tissue-selective recruitment of transcriptional cofactors (Norris et al. 1999, Klinge 2000, McKenna & O’Malley 2002, Belandia & Parker…”
BackgroundIdentification of an allosteric binding site for RORγt inhibition
Scheepstra, M., Leysen, S., van Almen, G. C., Miller, J. R., Piesvaux, J., Kutilek, V. D., van Eenennaam, H., Zhang, H., Barr, K., Nagpal, S., et al. (2015) · Nature Communications · doi:10.1038/ncomms9833 · Cited by 115
“Ligand binding in this pocket can activate or inhibit the receptor to various degrees 15 .”
Expression of Nuclear Receptors and Cofacotrs in Human Endometrium and Myometrium
Vienonen, A., Miettinen, S., Bläuer, M., MARTIKAINEN, P. M., Tomás, E. I., Heinonen, P. K., & Ylikomi, T. J. (2004) · Journal of the Society for Gynecologic Investigation · doi:10.1016/j.jsgi.2003.09.003 · Cited by 115
Schafer, J. M., Liu, H., Bentrem, D. J., Zapf, J. W., & Jordan, V. C. (2000) · PubMed · Cited by 116
Tip60 Is a Co-activator Specific for Class I Nuclear Hormone Receptors
Gaughan, L., Brady, M. E., Cook, S., Neal, D. E., & Robson, C. N. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103710200 · Cited by 98
Celik, L., Lund, J. D. D., & Schiøtt, B. (2007) · Biochemistry · doi:10.1021/bi061656t · Cited by 114
Barkhem, T., Nilsson, S. V., & Gustafsson, J. K. (2004) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200404010-00003 · Cited by 115
Self-citationStructure and mechanism of the oestrogen receptor
Kong, E. H., Pike, A. C. W., & Hubbard, R. E. (2003) · Biochemical Society Transactions · doi:10.1042/bst0310056 · Cited by 114
Self-citationXu, J., & O’Malley, B. W. (2002) · Reviews in Endocrine and Metabolic Disorders · doi:10.1023/a:1020016208071 · Cited by 114
ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases
Lopez-Garcia, J., Periyasamy, M., Thomas, R. S., Christian, M., Leao, M., Jat, P., Kindle, K. B., Heery, D. M., Parker, M. G., Buluwela, L., et al. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl875 · Cited by 117
“Binding of the ligand to the ligand binding domain (LBD), located C-terminal to the DBD, results in a conformational change in the LBD and activation of the intrinsic transcription activation function AF2, which facilitates the recruitment of transcriptional coactivators (7,8).”
BackgroundHuang, H.-J., Norris, J. D., & McDonnell, D. P. (2002) · Molecular Endocrinology · doi:10.1210/me.2002-0089 · Cited by 100
“Selective ER modulators (SERMs) such as raloxifene and tamoxifen, on the other hand, induce conformational changes in ER that interfere with the repositioning of H12 and alter the coactivator recruitment surface (7, 8).”
BackgroundNewman, S. P., Bates, N. P., Vernimmen, D., Parker, M. G., & Hurst, H. C. (2000) · Oncogene · doi:10.1038/sj.onc.1203416 · Cited by 115
“The formation of AF2 is dependent upon the integrity and alignment across the LBD of helix 12, a C-terminal amphipathic a-helix (Danielian et al., 1992; Brzozowski et al., 1997).”
BackgroundNorris, J. D., Fan, D., Stallcup, M. R., & McDonnell, D. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.12.6679 · Cited by 97
Ziegert, R. E., Toräng, J., Knepper, K., & Bräse, S. (2005) · Journal of Combinatorial Chemistry · doi:10.1021/cc049879v · Cited by 113
cDNA cloning and expression of a novel estrogen receptor β-subtype in goldfish (Carassius auratus)
Ma, C. H., Dong, K.-W., & Yu, K. L. (2000) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(99)00235-3 · Cited by 113
Savas, Ü., Griffin, K. J., & Johnson, E. F. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.5.851 · Cited by 113
“The accommodation of the antagonist tamoxifen by the ER-LBD appears to displace the AF-2 domain, and this is likely to prevent interaction with the coactivator (Brzozowski et al., 1997).”
Subramaniam, N., Treuter, E., & Okret, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.25.18121 · Cited by 99
Structural and functional insights into nuclear receptor signaling
Jin, L., & Li, Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.08.007 · Cited by 112
Frog: a FRee Online druG 3D conformation generator
Leite, T. B., Gomes, D. E. B., Miteva, M. A., Chomilier, J., Villoutreix, B. O., & Tufféry, P. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm289 · Cited by 112
“structure of raloxifene (PDB code 1err) (23) was predicted with FROG from a 2D SDF input file or a SMILES string.”
MethodMOLECULAR AND STRUCTURAL BIOLOGY OF THYROID HORMONE RECEPTORS
Apriletti, J. W., Ribeiro, R. C., Wagner, R. L., Feng, W., Webb, P., Kushner, P. J., West, B. L., Nilsson, S., Scanlan, T. S., Fletterick, R. J., et al. (1998) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.1998.tb02293.x · Cited by 102
Liganded and unliganded activation of estrogen receptor and hormone replacement therapies
Maggi, A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.05.001 · Cited by 93
“The accommodation of the ligand causes a reorientation of helix 12 toward the opening of the HBD allowing helices 3,5 and 12 to generate a novel activation function (AF) domain consisting of a hydrophobic grove on the LBD binding surface [13,14].”
Estrogen Receptor Domains E and F: Role in Dimerization and Interaction with Coactivator RIP-140
Peters, G. A., & Khan, S. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.2.0244 · Cited by 114
“If this is the case, crystal structure data of the ligand-binding domain (30) and DBD (8) of the ER must be reexamined in the context of the full receptor.”
BackgroundEstrogen receptor-mediated cross-talk with growth factor signaling pathways
Kato, S. (2001) · Breast Cancer · doi:10.1007/bf02967472 · Cited by 116
Westin, S. K., Rosenfeld, M. G., & Glass, C. K. (1999) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60110-6 · Cited by 112
Edman, K., Hosseini, A., Bjursell, M. K., Aagaard, A., Wissler, L., Gunnarsson, A., Kaminski, T., Köhler, C., Bäckström, S., Jensen, T. J., et al. (2015) · Structure · doi:10.1016/j.str.2015.09.012 · Cited by 111
Barreto, G., Santos-Galindo, M., Diz-Chaves, Y., Pernía, O., Carrero, P., Azcoitia, I., & Garcia-Segura, L. M. (2009) · Endocrinology · doi:10.1210/en.2009-0352 · Cited by 103
Bouton, D., Escrivá, H., de Mendonça, R. L., Glineur, C., Bertin, B., Noël, C., Robinson‐Rechavi, M., de Groot, A., Cornette, J., Laudet, V., et al. (2005) · Journal of Molecular Endocrinology · doi:10.1677/jme.1.01766 · Cited by 113
“…(A,S,I)(K,R,E,G)XXX(F,L)XX(L,V,I) www.endocrinology-journals.org Journal of Molecular Endocrinology (2005) 34, 567–582 XXX(D,S)(Q,K)XX (L,V)(L,I,F)) (Brzozowski et al. 1997, Xu et al. 1998, Kraichely et al. 1999), extending from the C terminal of H3 to the middle of H5, is completely conserved in…”
BackgroundMethodOostenbrink, C., Pitera, J. W., van Lipzig, M. M. H., Meerman, J. H. N., & van Gunsteren, W. F. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001045d · Cited by 111
Structural and functional analysis of domains of the progesterone receptor
Hill, K. K., Roemer, S. C., Churchill, M. E. A., & Edwards, D. P. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.07.017 · Cited by 96
“Antagonists bind to the LBD in a conformation that displaces helix 12 and disrupts or prevents formation of the AF2 interaction surface (Brzozowski et al., 1997; Shiau et al., 1998).”
BackgroundThe physiological role of estrogen receptor functional domains
Arao, Y., & Korach, K. S. (2021) · Essays in Biochemistry · doi:10.1042/ebc20200167 · Cited by 109
“Dimer structures of ligand-bound human ERα LBD have been reported previously [24, 25].”
BackgroundKallen, J., Lattmann, R., Beerli, R., Blechschmidt, A., Blommers, M. J. J., Geiser, M., Ottl, J., Schlaeppi, J.-M., Strauss, A., & Fournier, B. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703337200 · Cited by 95
S-palmitoylation modulates estrogen receptor α localization and functions
Marino, M., Ascenzi, P., & Acconcia, F. (2005) · Steroids · doi:10.1016/j.steroids.2005.09.011 · Cited by 109
Interdomain interactions in the mineralocorticoid receptor
Rogerson, F. M., & Fuller, P. J. (2003) · Molecular and Cellular Endocrinology · doi:10.1016/s0303-7207(02)00413-6 · Cited by 109
Garbán, H. J., Márquez-Garbán, D. C., Pietras, R. J., & Ignarro, L. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409854102 · Cited by 99
Fujita, T., Kobayashi, Y., Wada, O., Tateishi, Y., Kitada, L., Yamamoto, Y., Takashima, H., Murayama, A., Yano, T., Baba, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301031200 · Cited by 109
Dowsett, M., Bundred, N. J., DeCensi, A., Sainsbury, R., Lu, Y., Hills, M. J., Cohen, F. J., Veronesi, P., O'Brien, M. E. R., Scott, T., et al. (2001) · PubMed · Cited by 109
Lambert, M. N. T., Hu, L., & Jeppesen, P. B. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.151464 · Cited by 111
“As such, there is medical value in identifying surrogate bioactive substances with minimized and/or eliminated side effects of hormone therapies (9, 10).”
BackgroundSengupta, S., Obiorah, I. E., Maximov, P., Curpan, R. F., & Jordan, V. C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12122 · Cited by 108
“The molecular basis of this differential recruitment of the coregulators has been attributed to the ability of the liganded-ERa to reorient the helix 12 (H12) of the LBD in such a manner that the complex can interact with the coactivators at the structural interface formed by H3, H4 and H5 helices; when ERa is bound t…”
BackgroundInfluentialLorand, T., Vigh, E., & Garai, J. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710792927813 · Cited by 101
“Ligands interact with the ER LBD to modulate the position of helix 12 in distinct positions either favoring or disrupting co-activator binding [44].”
BackgroundOestrogenic and antiandrogenic chemicals in the environment: effects on male reproductive health
Akingbemi, B. T., & Hardy, M. P. (2001) · Annals of Medicine · doi:10.3109/07853890108995952 · Cited by 109
Digging deep into the pockets of orphan nuclear receptors: insights from structural studies
Benoit, G., Malewicz, M., & Perlmann, T. (2004) · Trends in Cell Biology · doi:10.1016/j.tcb.2004.05.007 · Cited by 108
Kitagawa, H., Yanagisawa, J., Fuse, H., Ogawa, S., Yogiashi, Y., Okuno, A., Nagasawa, H., Nakajima, T., Matsumoto, T., & Kato, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3698-3706.2002 · Cited by 101
“Comparison of the crystal structures of ligand-binding domains from several nuclear receptors revealed that cognate ligand binding induced the repositioning of the C-terminal -helical structure (H12) to form a hydrophobic groove, which then served as an interaction surface for AF-2 coactivators (7, 9, 18).”
BackgroundRetractedElectrostatic Modulation in Steroid Receptor Recruitment of LXXLL and FXXLF Motifs
He, B., & Wilson, E. M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2135-2150.2003 · Cited by 92
“For example, ER binding of raloxifene, a tissue-selective synthetic estrogen antagonist (5), or 4-hydroxytamoxifen (50) causes helix 12 to bind the core static region of the AF2 hydrophobic groove, whereas in the presence of the agonist 17 -estradiol, helix 12 contributes to the recognition surface of AF2 for LXXLL mo…”
BackgroundValentine, J. E., Kalkhoven, E., White, R., Hoare, S., & Parker, M. G. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002497200 · Cited by 103
Lin, X., Xiang, H., & Luo, G. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112689 · Cited by 94
Selective Oestrogen Receptor Modulators Decrease the Inflammatory Response of Glial Cells
Arevalo, M. A., Diz‐Chaves, Y., Santos‐Galindo, M., Bellini, M. J., & Garcia‐Segura, L. M. (2012) · Journal of Neuroendocrinology · doi:10.1111/j.1365-2826.2011.02156.x · Cited by 98
Metadata
- Authors
- Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å., & Carlquist, M.
- Affiliations
- University of York (GB)
- Karo Pharma (Sweden) (SE)
- University of Chicago (US)
- Corresponding author
- Hubbard, Roderick E.
- ORCID
- Venue
- Nature
- Published
- 1997-10
- Volume
- 389
- Issue
- 6652
- Pages
- 753-758
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2101738855
- Cited by
- 3,355
- References
- 29
- Citations by year
- 2026: 49 · 2025: 55 · 2024: 55 · 2023: 61 · 2022: 62 · 2021: 91 · 2020: 55 · 2019: 75 · 2018: 73 · 2017: 65 · 2016: 72 · 2015: 74 · 2014: 94 · 2013: 105 · 2012: 104
- FWCI
- 94.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Keywords
- oestrogen receptor, ligand-binding domain, estradiol, raloxifene, selective estrogen receptor modulators, crystal structure, transcriptional regulation
- MeSH terms
- Binding Sites, Estradiol, Estrogen Antagonists, Humans, Models, Molecular, Piperidines, Protein Conformation, Receptors, Estrogen, Crystallography, X-Ray, Raloxifene Hydrochloride
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.